External Content

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Sept. 22 (Bloomberg) -- Roche Holding AG intends to offer $5.75 billion of bonds to fund its pending acquisition of biotechnology company InterMune Inc., according to a person with knowledge of the transaction.

The six-part issue would be the first foray by the world’s largest maker of cancer drugs into the U.S. bond market since its sale of more than $16 billion of bonds in 2009.

Roche, based in Basel, Switzerland, agreed in August to buy InterMune, the Brisbane, California-based company for $8.3 billion in cash. The agreement reflects Roche’s confidence in pirfenidone, potentially the first drug in the U.S. for a rare lung disease that typically kills in five years. The drug is already sold in Europe, Canada and Japan.

The biggest portion of today’s offering will be $1.5 billion of five-year, fixed-rate notes that may yield 50 basis points more than similar-maturity Treasuries, according to the person who asked not to be named citing lack of authorization to speak publicly about the matter. A basis point is 0.01 percentage point.

Roche also plans to sell equal, $1.3 billion portions of 10-year and seven-year bonds, $850 million of three-year fixed- rate notes, $500 million of five-year, floating-rate securities and $300 million of three-year floaters, the person said.

To contact the reporter on this story: John Parry in New York at jparry5@bloomberg.net To contact the editors responsible for this story: Shannon D. Harrington at sharrington6@bloomberg.net John Parry, Faris Khan

Neuer Inhalt

Horizontal Line

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.

Click here to see more newsletters

The citizens' meeting

The citizens' meeting

The citizens' meeting